Stanford Cancer Institute

Cancer Cell Therapy

Non-Hodgkins Lymphoma

Diffused Large B-Cell Lymphoma

≥ 18 Yrs

Relapsed or refractory disease third-line

Will replace CCT5024 after it opens

End of Line

Relapsed or refractory disease after CD19-directed therapy

CCT5029
Phase I/II
Autologous CD22 CAR T-Cells in Adults w/ Recurrent or Refractory B-Cell Malignancies
Pi: Muffy
Sponsor: Stanford
Priority: 1st

CCT5062
Phase I/II
bbT369 Dual Targeting CAR T-Cell Drug Product w/ Gene Edit in Relapsed and/or Refractory B-Cell NHL
Pi: Ganjoo
Sponsor: 2seventy bio, Inc.
Priority: 2nd

CCT5041
Phase I
Anti-CD70 CRISPR-Cas9-Engineered T-Cells (CTX130) in Relapsed/Refractory T/B-Cell Malignancies
Pi: Weng
CRISPR

CCT5016
Managed Access Program (MAP)
CTL019 in ALL or DLBCL
Pi: Miklos
Sponsor: Novartis
Priority: 1st

CCT5001
Phase I
CD19/CD22 Chimeric Antigen Receptor (CAR) T-Cells in Recurrent/Refractory B-Cell Malignancies
Pi: Miklos
Stanford
Priority: 2nd

CCT5024
Phase I/II
ALLO-501 (Anti-CD19 Allogeneic CAR T-Cell Tx) in Relapsed/Refractory Large B-Cell & Follicular Lymphoma
Pi: Miklos
Allogene

CCT5043
Phase I Study of FT819 in B-cell Malignancies
Pi: Miklos
Sponsor: Fate Therapeutics, Inc.

CCT5067

KEY

- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu